Effects of Pathogen-Vector Interactions on the Transmission of Dengue Virus

From MicrobeWiki, the student-edited microbiology resource
Jump to: navigation, search
This is a curated page. Report corrections to Microbewiki.

Dengue Virus

Figure 1. Electron micrograph of dengue virus (DENV).[1]



Group IV: ss(+)RNA virus
Family: Flaviviridae
Genus: Flavivirus

Figure 2. Main vector of dengue virus, Aedes aegypti or the Asian tiger mosquito.[2]


Dengue virus (DENV) is the causative agent of both classical dengue fever, and the more severe dengue hemorrhage fever (DHF) and dengue shock syndrome (DSS)[4]. It is most commonly transmitted by the mosquito vector Aedes aegypti as seen in figure 2, but can be transmitted by other members of the genus Aedes including Aedes albopictus[5]. There are four different DENV serotypes of dengue virus (DENV 1-4). Infection with one serotype affords life-long immunity to that serotype but only partial (heterologous) immunity to other serotypes for a short period of time post-infection. After a period of initial protective immunity, the risk of developing DHF or DSS upon reinfection with another dengue virus from a different serotype increases.

This increased risk for severe dengue is the result of antibody-dependent enhancement of viral infection. Host heterotypic non-neutralizing antibodies from previous DENV infection bind DENV virions. If infection was recent there are enough antibodies to neutralize any newly infecting dengue viruses but overtime the number of neutralizing antibodies drops. At some point there are so few enough antibodies left that upon reinfection with a new strain antibodies can bind but not neutralize the virus. The constant region of the antibody can go on to bind an FcγR receptor on the surface of an immune cell. Normally, when a pathogen-antibody complex binds to a FcγR receptor a cytoxic or phagocytotic response is initiated by that particular type of immune cell. DENV somehow avoids this response and instead binds its host cell surface receptor . Figure 3 shows DENV virions binding to the host cell surface receptor under subnuetralizing levels of antibodies.

Figure 3. Antibody-dependent enhancement of DENV infection, adapted from Takada and Kawaoka, 2003. [3]


The FcγR receptor response is effective in controlling other pathogens, but DENV has evolved to exploit this pathway. The FcγR receptor is not needed for DENV entry but does increase infectivity DENV and allows it to display cell tropisms not seen in primary DENV infection [3]. With more cells infected, the more virions produced, leading to higher titers of virus in the blood. high viremias are correlated with increased risk for DHF and DSS [3,23].

Within serotypes dengue viruses are organized by genotypes, subtypes, clades, variants, groups and finally strains [3]. The large number of dengue strains in the world combined with only partial crossover immunity to other strains makes concurrent (multi-strain) infections or reoccurring dengue infections possible (just like repeated bouts of the flu), especially in areas with high prevalence of DENV.

Dengue viruses are now endemic in many tropical parts of the world. This put about a third of the world’s population at risk of infection. There are estimated to be over one hundred million new infections per year and rising [5,6]. Rising rates of infection are the result changes in vector populations and range. vector control in areas that need it most has been cutback and global warming has expanded vector ranges to areas previously DENV free. Milder winters at higher latitudes has allowed adult and larvae mosquitoes to survive longer into the fall and return earlier in the spring for a more or less continuous DENV transmission cycle. DENV is becoming a threat to industrialized nations once thought to be too far away from the tropics for Dengue fever to be a threat. In the U.S., the number of indigenous dengue cases is rising. In Brownsville Texas, 25% of the residents who had never traveled outside the united states had antibodies indicating prior exposure to DENV [6,7].

The severity of dengue infection also continues to increase. The ratio of DHF and DSS cases to classical dengue fever has increased dramatically over the past sixty years. Dengue infection-related complications have become the leading cause of hospitalization and death in children in several endemic countries [7].

Dengue Fever, Dengue Shock Syndrome, and Dengue Hemorrhagic Fever

Figure 4. Ecchymosis (bleeding under the skin) associated with dengue hemorrhage fever.[6]

Although classical dengue fever is not usually fatal it has very high morbidity; its alternate name is break-bone fever because of the severe joint pain during infection. DENV infection is most common in infants, young children, and adults. Classical dengue fever manifests as a red rash with mild to high fever, debilitating headaches, muscle and joint pain.

The more severe manifestations of DENV infection are dengue hemorrhage fever and dengue shock syndrome. Young children and those with antibodies from previous DENV infection are most at risk for these complications because of antibody-dependent enhancement of infection[5].

Dengue shock syndrome results from DENV infection of the endothelial cells lining the blood vessel [17]. When these cells become damaged by infection the integrity of the blood vessels is compromised, and plasma leaks out, causing a host of systemic problems including edema and hypotension. Edema is the result of tissue swelling from an influx of plasma with nowhere to go and can cause severe abdominal pain. Hypotension is low blood pressure resulting from a drop in total blood volume from plasma loss. Edema and hypotension both impede proper circulation. Oxygen and nutrients stop reaching the body's tissues leading to shock and death if left untreated [6].

Dengue hemorrhage fever occurs when normal blood coagulation is disrupted by infection. Fever, emesis (vomiting), and hemorrhaging (bleeding) are all symptoms common to this type of DENV infection[5]. The results of internal hemorrhaging are visible in the form of tiny red spots (petechiae) or sometimes black patches under the skin (ecchymosis)as seen in Figure 4. Bloody stool (feces) and bleeding from the gums and nose is also common[5]. Mortality from these complications can be up to 14% without proper care [4].

Unfortunately there are no anti-viral drugs for DENV infection. The only treatment is supportive care; fluid replacement and pain management [5]. With no licensed vaccine, disruption of the vector-host transmission cycle is the only form of disease control. To stop transmission from host to vector, those infected only need to prevent further exposure to mosquitoes through the use of mosquito nets as shown in Figure 5.

Figure 5. Patient recovering from dengue fever. Note the mosquito net over the patient's bed in order to prevent transmission of virus to a new vector host. [12]



Figure 6. Beware of the Bite; poster warning residents to avoid mosquito bites in areas with high prevalence of dengue fever.[11]



Controlling DENV transmission between vector and host populations is simple, but labor-intensive and costly. In the past heavy pesticides such as DDT were used to wipe out mosquito populations, but this has fallen out of favor because of their toxic effects [7]. Nowadays, active disease control centers on public health campaigns with posters (like in Figure 6) urging citizens to get rid of standing water in and around their homes and seek treatment if they have dengue fever-like symptoms. Current DENV education campaigns and vector control programs are not as cost-effective as other public programs and this has led to a decrease in government funding over the years in tropical areas that need it most. In an attempt to find a more efficient and cost-effective form of vector control, researchers are trying to understand the complexities of dengue virus replication in mosquito vectors. Co-infection of the mosquitoes with multiple DENV strains or the bacterium Wolbachia and interactions between DENV and the mosquitoes’ innate immune system all modulate viral replication. The replication kinetics of DENV in the mosquito-host have overreaching effects on the epidemiology of the disease [5].With a better understanding of how each of these factors affects the overall viral load and rate of viral replication with in the vector. It will be possible to come up with better strategies for vector transmission control to mitigate and prevent future DENV epidemics (Figure 7).

Figure 7. Simplified epidemiological triad for dengue virus transmission. Note the number of factors that influence DENV replication in mosquito vector.


Types of DENV Strains


There are multiple classifications for DENV strains depending on the context. DENV strains maintaining transmission mostly between nonhuman primates and forest dwelling Aedes aegypti are considered sylvatic. It was once thought that sylvatic strains were less virulent than epidemic or endemic strains of DENV. Some believed sylvatic strains lacked the potential to cause virulent epidemics because cases of sylvatic dengue fever are rare when compared to overall incidence of dengue fever. As it turns out, sylvatic strains share the same pathogenic potential as strains found in urban areas, cases of dengue hemorrhagic fever from sylvatic DENV infection have even been reported. The destruction of forest areas where sylvatic strains of DENV are maintained has not even lead to a decrease in outbreaks of sylvatic DENV in West Africa [18].

Epidemic and endemic DENV strains infect and replicate within humans and domesticated Aedes species [9]. The distinction between epidemic and endemic dengue has become hazy as epidemic strains of DENV have become endemic in tropical urban slums. In areas where there is poor sanitation, free standing water, high population density, and constant human traffic there is continuous disease transmission [4,8]. Epidemic strains of DENV are best transmitted by Aedes aegypti mosquitoes but can be transmitted less efficiently by other Aedes species [19]. Epidemic strains have the potential to produce large fast moving epidemics, but there must be high density vectors and susceptible host populations in close proximity to one another [20].

Invasive species are defined as strains or genotypes of DENV not previously seen in a particular area or geographic region [14]. They tend to cause large epidemics because the population in that area does not have homologous immunity to the virus. Noninvasive species are endemic to the area and maintain slow continued transmission. Invasive species can be more virulent than noninvasive strains but this is dependent on host population susceptibility to all of the strains of DENV circulating in the area at that given time. An invasive strain can colonize a given area if it can out-compete other DENV strains for susceptible hosts, eventually becoming an established strain endemic to the area. The differentiation between invasive and noninvasive is an arbitrary term often used to differentiate between established and new species of DENV.

DENV can also be classified according to genotype. The two most common genotypes mentioned in the literature are American and Southeast Asian because of their well-documented differences in virulence. American genotype strains tend to be less virulent as well as less competitive than Southeast Asian genotype strains.

Viral Replication



Figure 8. DENV (+)ssRNA genome and schematic of viral replication within host cell.[21]



DENV infection begins at the cellular level when E envelope glycoproteins on the surface of a DENV virion binds to a host cell receptor initiating endocytosis. The high cell tropism of DENV has made the elucidation of a single host cell receptor difficult and the exact host cell receptor or receptors responsible for viral entry remain to found [22].

Once endocytosed, DENV escapes the endosome to the cytoplasm where it can immediately begin translation of its genome. Like other (+)ssRNA viruses it must transcribe a negative strand RNA template to make new copies of its genome.

























Transmission Cycle


Figure 9. DENV transmission cycle between human hosts and mosquito vectors.[10]


The DENV transmission cycle begins when an infected mosquito bites a human or nonhuman primate host. The Host begins to experience symptoms four to seven days post-infection. Symptoms usually lasting three to ten days after which, there is about a three week convalescence [8]. The virus initially replicates in target organs like the liver, spleen, and thymus but eventually makes its way to the lymphatic system where it replicates in lymph tissue and white blood cells. The lymphatic system serves as a gateway to the bloodstream where the virus continues to replicate and can potentially infect the endothelial cells of the circulatory vasculature. Eventually virus titers are high enough in the host’s bloodstream for disease transmission to occur. For a period of about five days, just before symptoms appear, the virus is transmissible to a new mosquito vector through an infected blood meal.

After DENV is taken up in an infected blood meal it replicates in the midgut of the insect and infects its hemocoel (body cavity). From the hemocoel, the virus eventually infects the salivary glands. Once virus titers are high enough in the salivary glands the mosquito can infect a new susceptible host during its next blood meal [4]. The length of time required for virus to reach the salivary glands of a mosquito after the ingestion of an infected blood meal is about eight to ten days depending on both viral and host factors [8]. The delay between ingestion of an infected blood meal and infection and replication of DENV in the salivary glands influences the course of epidemics and plays a role in competition between DENV strains.



Viral Factors Affecting DENV Replication and Transmission in Mosquito Vector

Figure ?. positive correlation between percent of heads infected (arcsine-square root transformation)and the mean body virus titer in mosquitoes infected with DENV-3 strains.[4]

The transmission from vector to host for a particular DENV strain is determined by viral infectivity of mosquito cells and the rate of viral replication in these cells. Dissemination from the hemocoel to the salivary glands affects disease transmission as well but it is tied to viral replication rates and viral titers in the hemocoel as seen in Figure 10[4]. Replication rate and viral titers are both correlated with genotypic differences between DENV strains. Strains belonging to more virulent genotypes have fast rates of viral replication as well as higher virus titers in human and vector hosts[4,23]. Figure 11 shows higher virus titers in mosquito bodies from mosquitoes infected with virulent invasive DENV-3 strains and noninvasive DENV-3 strains [4].

Figure 11.Invasive and noninvasive DENV-3 strains viral titers in infected mosquitoes.[4]


















Figure 12. Predicted secondary RNA structures of the 3’ NTR of; a, an American genotype DENV-2 strain and b, a Southeast Asian DENV-2 strain.[23]













Differences in the encoded secondary structure of non-translated regions of the RNA genome (NTRs) are correlated with differences in virulence between strains. No specific nucleotide or amino acid differences in either the coding or noncoding region have been correlated with attenuated disease in humans. It is only clear that there are differences at these sights between more virulent strains and less virulent strains. differences in the three dimensional structure of the NTR regions as shown in Figure 12 may affect the initiation of translation. This could explain why more virulent strains have higher rates of replication. Mutations in the sequence with in the envelope glycoprotein E have also been correlated with virulence but as of yet there are no specific changes in nucleotide sequence correlated with virulence [23].













Vector Host-Factors Affecting DENV Replication and Transmission in Mosquito Vector


The Aedes vector's innate immune response to DENV infection influences the rate of DENV replication, which influences the lag period between initial infection in the mosquito and disease transmission between mosquito and host (extrinsic incubation period)[4,6].

Mean DENV titers in infected mosquitoes can be modulated by blocking the function of one or more components in the RNA interference (RNAi) pathway. This innate immune response is triggered by the presence of dsRNA in an infected cell. In the case of DENV infection the secondary structure of the NTR of the RNA genome may trigger this response. The hairpin loops as seen in Figure 12 look like dsRNA[24]. Activation of the RNAi pathway leads to the degradation of ds-like RNA within the infected cell. Although it does not completely inhibit infection, virus titers are lower in mosquito cells with a functional RNAi response than mosquito cells without a mutant or disabled response [24]. DENV dsRNA can also activate Toll pathways in infected mosquito cells. Active Toll pathways upregulate the production of a number of different peptide antimicrobials meant to destroy the virus [25].

The presence of bacterial flora in the gut of mosquitoes also upregulate the mosquito vector's Toll pathway response, creating an immune response that keeps gut microbiota in check as well as limiting DENV replication. In figure ? the DENV titers in the midgut of infected mosquitoes raised in a microbe free environment (aseptic) are much higher than mosquitoes raised under normal conditions [25].

Figure 13. Mosquitoes raised under aseptic conditions (no microbial flora) had more DENV in their midgut tissue than septically raised mosquitoes (have microbial flora).[25]


Infection of the bacterium Wolbachia decreases the ability of mosquito vectors to transmit DENV by shortening the life-span of the vector. The less time a mature vector with high DENV titers is around potentially biting people the less chance there is for disease transmission. Over-replication of Wolbachia in host cells also seems to be responsible for changes in vector feeding behavior leading to fewer successful transmissions from mosquito to host during blood-feeding. Intentional infection of vector populations with wolbachia is currently being considered as a novel bio-control strategy in vector control [13,26].







Competitive Strain Displacement Between Dengue Strains


There are multiple ways a strain prevalent in a given geographic area can change. A strain can evolve over time until it is antigenetically different enough from the original strain so that infection with the original parent strain does not confer homologous immunity to this daughter strain making it a new strain [4]. Strains can go extinct in a given geographic area because there are no more susceptible human hosts left leaving room for a strain prevalent in given in an area to take over. Or, a new strain can be introduced to an area and outcompete existing strains for susceptible hosts. Competitive strain displacement has been documented in epidemiological data as well controlled studies involving co-infection of multiple strains of dengue in a single host [14].

Competitive strain displacement occurs when a more virulent strain of DENV competes with a less virulent strain, resulting in a shift in strain frequency. Competition occurs during singular strain infection of a DENV vector or co-infection of a vector with multiple strains of DENV. In singular infection of a vector the more virulent strain can replicate and disseminate faster in the vector host decreasing the extrinsic incubation period. A shorter viral incubation period in the vector increases the number of days a mosquito is infectious and potentially transmitting disease. The longer the mosquito is infectious before it dies the more people can be infected by this strain. The more virulent strain has a greater chance of being transmitted from vector to host and increasing the number of DENV infections due to this particular strain in a given population.

Competitive strain displacement is also seen during co-infection of a vector with or more strains of DENV. The more virulent strain tends to be able to replicate faster increasing the ratio between more virulent virus particles and less virulent virus particles. Figure 14 shows the results of vector co-infection between virulent strains of the Southeast Asian genotype and less virulent strains of the American genotype. The more virulent Southeast Asian genotype strains infected a higher percentage of mosquitoes than any of the American genotype strains after mosquitoes ingested infected blood meals [23].

Figure 14. Results of co-infection of mosquito vectors with a more virulent strain (Southeast Asian genotype) and less virulent strain (American genotype).[23]

Again, competition is a numbers game. The mosquito vector can transmit both strains of the virus equally but, if there is a higher viral titer of one strain over another, the co-infected vector will be more likely to transmit the strain with the higher viral titer to a new host.

It makes sense that more virulent strains are also more competitive. Virulence in humans is correlated with increased levels of viremia [23]. High viremia results from increased systemic infection because of increased infectivity and replication in host cells. The phenomenon of virulent strains also being more competitive than less virulent strains is one way to explain the increase in the number of severe cases of dengue over the past fifty years and the global turnover of dengue strains. The distribution of dengue serotypes in areas with endemic dengue has not changed over the years but the prevalence of different genotypes, subtypes or groups (that have varying levels of virulence in humans) continues to change around the globe. Invasive strains (new to a given geographic area) tend to be more virulent than the native strain already present and therefore are able to become more prevalent than the native strain through competitive displacement [4,13].

In Sri Lanka in the 1980’s a virulent invasive DENV3 strain was introduced that eventually displaced the native DENV3 strain resulting in a dramatic increase in the number of severe dengue cases. Since the 1980’s all four dengue serotypes have been circulating freely in Sri Lanka but only after 1989 was there a sharp rise in cases of dengue hemorrhagic fever and dengue shock syndrome [14].

Competitive strain displacement also occurs on the human side of the viral life cycle but is not as much of a concern when looking at ways to prevent the spread of more virulent dengue strains because of methods of transmission control already discussed.

Vectorial Capacity of DENV Strains


Figure 15. Equation for Vectorial capacity.[13]

Vectorial capacity is the frequency at which a mosquito bites and can potentially transmit infection to a human host following ingestion of an infected blood meal. It is determined by a number of factors shown in Figure 15. Vectorial capacity is key in modeling the dengue fever epidemics. With an increased understanding of the factors that influence DENV infection in mosquitoes, epidemiologists can fine tune the parameters used to determine vectorial capacity and come up with better models to predict future outbreaks.













Epidemiologic Consequences of Various Forms of Vector Control


Even slight changes in the pathogen-vector dynamic at the cellular level can affect dengue virus transmission. Minute changes of virus titers in the salivary glands, rate of dissemination of virus from the midgut to the salivary glands as well as a slew of other changes due to pathogen-vector dynamics can have a far reaching impact on the epidemiology of DENV infections. With a better understanding of the involvement of dengue virus genotype and vector host factors in disease transmission it may be possible to manipulate one of these factors that influence the pathogen-vector dynamic to help prevent further spread of dengue fever even without dengue specific drugs or a vaccine.


References


[1] Cann, A., September 25, 2007. “Dengue virus” Flickr. Available: http://www.flickr.com/photos/ajc1/1437910835/ [Date visited: 12/7/10]

[2] Funchal Camara Municipal. “Monitoring the Yellow Fever Mosquito” Funchal Camara Municipal. Available: http://www.cm-funchal.pt/Cmf/en/Default.aspx?ID=110 [Date visited: 11/1/10]

[3] Takada, A., Y., Kawaoka. 2003. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13: 387-398

[4] Hanley, K.A., J.T., Nelson, E.E., Schirtzinger, S.S., Whitehead, C.T., Hanson. 2008. Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus. BioMed Central Ecology 8(1)

[5] Centers for Disease Control and Prevention. October 28, 2010. “Dengue” Available: http://www.cdc.gov/dengue [Date visited: 10/28/10]

[6] Dengue Fever. 2010. “Dengue Fever Symptoms” denguefeversymptoms.org. Available: http://www.denguefeversymptoms.org/ [Date visited: 10/31/10]

[7]Marsa, L. 2010. The hot zone. Discover December 2010

[8] World Health Organization. 2010. “Dengue” Available: http://www.who.int/topics/dengue/en/ [Date visited: 10/27/10]

[9] Pepin, K.M., K.A., Hanley. 2008. Density-dependent competitive suppression of sylvatic dengue virus by endemic dengue virus in cultured mosquito cells. Vector Borne Zoonotic Diseases. 8(6): 821-828

[10] Prima Quality Media. 2010. “gdeng052.gif” Available: http://www.primaquality.com/2008/03/30/combating-of-dengue-hemorrhagic-fever-scourge/cyrcle-transmission-of-dengue-virus/ [Date visited: 10/29/10]

[11] Genesio, J.. May 21, 2010. “Beware of the Bite” Natural Unseen Hazards Blog. Available: http://naturalunseenhazards.wordpress.com/2010/05/21/recent-outbreak-of-dengue-cases-are-the-first-locally-acquired-cases-in-florida-since-1934/ [Date visited: 10/30/10]

[12] Worldnews Infectious Disease. 2010. “Recovering dengue fever patient” Available: http://wn.com/infectious_disease [Date visited: 10/28/10]

[16] Moreira, L.A., I., Iturbe-Ormaetxe, J.A., Jeffery, G., Lu, A.T., Pyke, L.M., Hedges, B.C., Rocha, S., Hall-Mendelin, A., Day, M., Riegler, L.E., Hugo, K.N., Johnson, B.H., Kay, E.A., McGraw, A.F., Van Den Hurk, P.A., Ryan, S.L., O’Neill. 2009. A Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and plasmodium. Cell. 139: 1268-1278

[13] Anderson, J.T., R., Rico-Hesse. 2006. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. American Journal of Tropical Medicine and Hygiene. 75(5):886-892

[14] Messer, W.B., U.T., Vitarana, K., Sivanathan, J., Elvitgala, L.D., Preethimala, R., Ramesh, N., Withana, D.J., Gubler, A.D, Silva. 2002. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. American Journal of Tropical Medicine and Hygiene. 66(6):765–773

[15] Leitmeyer, K.C., D.W., Vaughn, D.M., Watts, R., Salas, I., Villalobos de Chacon, C., Ramos, R, Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. Journal of Virology. 73(6):4738-4747

[17] Srikiatkhachron, A. 2009. Plasma leakage in dengue haemorrhagic fever. Thromb. Haemost.. 102(6):1042-1049

[18] 2010. Letter to the Editor: sylvatic dengue viruses share the pathogenic potential of urban/endemic dengue viruses.Journal of Virology. 84(7):3726-3728

[19] Ooi, E., D.J., Gubler. 2008. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention.Cad. Saude Publica, Rio de Janeiro. 1:S115-S124

[20]Honorio, N.A., R.M.R., Nogueira, C.T., Codeco, M.S., Carvalho, O.G., Cruz, M., de Avelar Figueiredo Marfa Magalhaes, J.M., Galvo de Araujo, E.S., Machado de Araujo, M.Q., Gomes, L.S., Pinheiro, C.D.S., Pinel, R., Lourenco-de-Olivera. 2009. Spatial evaluation and modeling of dengue seroprevalence and vector density in Rio de Janeiro, Brazil. PLOS, Neglected Tropical Disease. 3(11):1-11

[21]New approaches to structure-based discovery of dengue protease inhibitors. 2010. “Simple representation of Neuraminidase N1 virtual screening using WISDOM grid production environment.” Available: http://www.dsimb.inserm.fr/~debrevern/IDDT-2009_in_silico_issue/iddt_2009_in_silico_issue.php [Date visited: 12/5/10]

[22] Acosta, E.G., L.B., Talarico, E.B., Damonte. 2008. DENV attachment: multiple cell receptors? Future Virology. 3(5):471-479

[23] Cologna, R., P.M., Armstrong, R., Rico-Hesse. 2004. Selection for virulent dengue viruses occurs in humans and mosquitoes Journal of Virology. 79(2):853-859

[24] Sanchez-Vargas, I., J.C., Scott, B.K., Poole-smith, A.W.E., Franz, V., Barbosa-Solomieu, J., Wilusz, K.E., Olson, C.D., Blair. 2009. Dengue viruse type 2 infections of Aedes aegypti are modulated by the mosquitoes’ RNA interference pathway. PLOS, Pathogens. 5(2):1-11

[25] Xi, Z., J.L., Ramirez, G., Dimpopoulos. 2008. The Aedes aegypti Toll pathway control dengue virus infection. PLOS, Pathogens. 4(7):1-11

[26] Turley, A.P., L.A., Moreira, S.L., O’Neil, E.A., McGraw. 2009. Wolbachia infection reduces blood-feeding success in the dengue fever mosquito, Aedes aegypti . PLOS, Neglected Tropical Diseases. 3(9):1-11

Page authored by Kelly Wahl for BIOL 375 Virology, 2010